Delivery Order SPE2DB25D3008-SPE2DB25FRDJE
Award Date 9/23/25
Potential Completion Date 9/24/25
Potential Value $27K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $5,099.34 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, making this...
- The Defense Logistics Agency awarded a delivery order valued at $10,969.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was placed under no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $6,223.32 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for RINVOQ ER 15 mg tablets in quantities of 30 units. The contract, which is non-set-aside and competitively awarded, carries a firm fixed price structure with performance to be completed by August 1, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $29,548.30 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis...
- The Defense Logistics Agency awarded a delivery order valued at $6,639.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 9, 2025, with completion expected by June 10, 2025. This firm fixed price delivery order was competitively awarded without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis...
- The Defense Logistics Agency awarded a $23,345.53 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used in the treatment of rheumatoid...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (Unit of Use, 30-count) valued at $10,818.81 under firm fixed price terms. This non-set-aside, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment...